Annual Report

The report highlights Biocon and Mylan's first-to-file applications for biosimilar Trastuzumab in the US and EU, alongside progress across the biosimilar pipeline. It reports a group employee base of 9,234 as of March 2017. The company also states that green power accounted for 28% of total energy consumption during FY17.